Valeant Architect Bets On Drugmaker by Returning to the Board

  • ValueAct's Mason Morfit rejoins company he helped shape
  • SEC rules likely prevent ValueAct from adding shares for now

ValueAct Capital Management helped make Valeant Pharmaceuticals International Inc. what it is today -- and now the activist fund is stepping up to defend its creation.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.